Pfizer breaks off German pricing talks, withdraws Bosulif

Pfizer Inc. (NYSE:PFE) broke off pricing negotiations with Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband) for Bosulif bosutinib and said it will no longer market the Orphan cancer drug in Germany. Pfizer said there was "no prospect of reaching an agreement" on Bosulif's price after the first round of negotiations. Last month, Germany's Federal Joint Committee (G-BA) said Bosulif has an "unquantifiable" additional benefit for adults with chronic, accelerated or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) -- the indication for which the dual inhibitor of BCR-ABL and Src kinase has conditional approval in the EU (see BioCentury Extra, Oct. 17). ...